510 related articles for article (PubMed ID: 19424051)
1. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
2. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Rivas P; Górgolas M; García-Delgado R; Díaz-Curiel M; Goyenechea A; Fernández-Guerrero ML
HIV Med; 2008 Feb; 9(2):89-95. PubMed ID: 18093130
[TBL] [Abstract][Full Text] [Related]
3. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
4. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy.
van Vonderen MG; Hassink EA; van Agtmael MA; Stehouwer CD; Danner SA; Reiss P; Smulders Y
J Infect Dis; 2009 Apr; 199(8):1186-94. PubMed ID: 19275490
[TBL] [Abstract][Full Text] [Related]
5. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
6. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
8. Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.
Kolta S; Flandre P; Van PN; Cohen-Codar I; Valantin MA; Pintado C; Morlat P; Boué F; Rode R; Norton M; Knysz B; Briot K; Roux C; Delfraissy JF
Curr HIV Res; 2011 Jan; 9(1):31-9. PubMed ID: 21198431
[TBL] [Abstract][Full Text] [Related]
9. Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy.
van Vonderen MG; Blümer RM; Hassink EA; Sutinen J; Ackermans MT; van Agtmael MA; Yki-Jarvinen H; Danner SA; Serlie MJ; Sauerwein HP; Reiss P
J Acquir Immune Defic Syndr; 2010 Feb; 53(2):186-93. PubMed ID: 19898246
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD;
Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
12. Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
Sripan P; Le Coeur S; Ingsrisawang L; Cressey TR; Bouazza N; Foissac F; Ngo-Giang-Huong N; Traisathit P; Srirompotong U; Ayudhaya OP; Puangsombat A; Jungpipun J; Jittayanun K; Tréluyer JM; Jourdain G; Lallemant M; Urien S
Antivir Ther; 2016; 21(5):435-40. PubMed ID: 26492107
[TBL] [Abstract][Full Text] [Related]
13. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
16. Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies.
Briot K; Kolta S; Flandre P; Boué F; Ngo Van P; Cohen-Codar I; Norton M; Delfraissy JF; Roux C
Bone; 2011 May; 48(5):1133-9. PubMed ID: 21276883
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
[TBL] [Abstract][Full Text] [Related]
18. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Clumeck N; Mwamba C; Kabeya K; Matanda S; Vaira D; Necsoi C; Kadiebwe D; Delforge M; Kasamba E; Milolo C; Ilunga J; Kapend L
AIDS; 2014 May; 28(8):1143-53. PubMed ID: 25028911
[TBL] [Abstract][Full Text] [Related]
19. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
